NCT00861419View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2005

Conditions
Advanced Solid Tumors
Interventions
DRUG

Sorafenib

Sorafenib 400 mg PO (BID)

DRUG

AMG 706

AMG 706 125 mg PO (QD)

DRUG

AMG 706

AMG 706 75 mg PO (QD)

DRUG

AMG 386

AMG 386 10 mg/kg IV (QW)

DRUG

Sunitinib

Sunitinib 50 mg PO (QD)

DRUG

Bevacizumab

Bevacizumab 15mg/kg IV Q3W

DRUG

AMG 386

AMG 386 3 mg/kg IV (QW)

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00861419 - To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | Biotech Hunter | Biotech Hunter